← Human Trials & Peer-Reviewed Studies
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes
Plain-language guide to PMID 15735200 (2005): single-blind randomized controlled trial study of Amylin (Islet Amyloid Polypeptide) in 18 subjects.
Key Facts
- PMID
- 15735200
- Journal
- Diabetes care
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Ceriello A et al. (9 authors)
- DOI
- 10.2337/diacare.28.3.632
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.
Who Took Part
The study group was 18 subjects.
PubMed indexes the participants as adults and middle-aged adults, men only.
In a randomized, single-blind, placebo-controlled, crossover study, 18 evaluable subjects with type 1 diabetes underwent two standardized breakfast meal tests and received pramlintide or placebo in addition to their preprandial insulin.
How the Study Was Run
The design is described as randomized, single-blind, placebo-controlled and crossover.
The subjects were allocated by chance, so the Amylin (Islet Amyloid Polypeptide) group and the comparison group should start out alike.
In this single-blind Amylin (Islet Amyloid Polypeptide) study one party knew the assignments and the other did not.
Some subjects received a placebo instead of Amylin (Islet Amyloid Polypeptide), giving a reference point.
Each person switched between Amylin (Islet Amyloid Polypeptide) and the comparison at some point, usually with a gap in between.
The plasma concentrations of glucose and markers of oxidative stress (nitrotyrosine, oxidized LDL [ox-LDL], and total radical-trapping antioxidant parameter [TRAP]) were measured at baseline and during the 4-h postprandial period.
What Was Measured
The subject headings attached to it are Amyloid, Blood Glucose, Diabetes Mellitus, Type 1, Enzyme-Linked Immunosorbent Assay, Glycated Hemoglobin, Hypoglycemic Agents and Islet Amyloid Polypeptide.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide) in 18 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2005 (Diabetes care), a journal based in United States.
More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.
Our Notes on the Compound
Amylin (Islet Amyloid Polypeptide): A 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.